Ado-trastuzumab emtansine Biosimilar - Research Grade, Low Endotoxin

Ado-trastuzumab emtansine Biosimilar - Research Grade, Low Endotoxin

Catalog Number:
A001437364ICH
Mfr. No.:
ICH4014
Price:
$1,602
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Specificity: Detects human HER2. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Ado-trastuzumab emtansine.
          Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
          Isotype Control: Bulk Human IgG1 Isotype Control (IB1) [ICH2254]
          Endotoxin: ≤ 0.75 EU/mg as determined by the LAL method

          Please contact us at for specific academic pricing.

          Background

          Ado-trastuzumab emtansine is a HER2-targeted antibody-drug conjugate which contains the humanized anti-HER2 IgG1, trastuzumab, covalently linked to the microtubule inhibitory drug DM1 via the stable thioether linker MCC. Trastuzumab is produced by Chinese hamster ovary cells, and DM1-MCC are produced by chemical synthesis. Ado-trastuzumab emtansine contains an average of 3.5 DM1 molecules per antibody.

      • Properties
        • Host
          humanized
          Isotype
          IgG1
          Reactivity
          human
          Purification
          >95% by SDS-PAGE and HPLC
          Formulation
          Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.
          Storage
          Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.
          Molecular Weight
          1.0 - 5.0 mg/ml

          * Products are for research use only. Not for use in diagnostic or therapeutic procedures.

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.